United Capital Financial Advisers LLC reduced its stake in Eli Lilly and Company (NYSE:LLY) by 4.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 70,128 shares of the company’s stock after selling 3,058 shares during the period. United Capital Financial Advisers LLC’s holdings in Eli Lilly and were worth $5,898,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Heritage Trust Co purchased a new position in Eli Lilly and in the 1st quarter worth approximately $135,000. Penserra Capital Management LLC increased its stake in Eli Lilly and by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after purchasing an additional 176 shares during the period. Crestwood Advisors Group LLC purchased a new position in Eli Lilly and in the 1st quarter worth approximately $179,000. Sandy Spring Bank increased its stake in Eli Lilly and by 51.8% in the 1st quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after purchasing an additional 750 shares during the period. Finally, Coldstream Capital Management Inc. purchased a new position in Eli Lilly and in the 1st quarter worth approximately $200,000. 75.77% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company (LLY) traded up 0.43% during midday trading on Wednesday, hitting $80.16. The company had a trading volume of 917,759 shares. The stock has a 50 day moving average price of $81.21 and a 200 day moving average price of $82.05. The company has a market capitalization of $84.57 billion, a P/E ratio of 34.69 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. Eli Lilly and also saw unusually large options trading on Monday. Stock traders bought 7,401 put options on the stock. This represents an increase of 342% compared to the average volume of 1,675 put options.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the business posted $0.86 EPS. Equities analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a yield of 2.61%. Eli Lilly and’s payout ratio is currently 90.04%.

WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/06/united-capital-financial-advisers-llc-has-5-90-million-holdings-in-eli-lilly-and-company-lly.html.

A number of brokerages have commented on LLY. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a research note on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $93.00 price target on shares of Eli Lilly and in a research note on Thursday, June 22nd. Deutsche Bank AG reaffirmed a “buy” rating and issued a $91.00 price target (up from $90.00) on shares of Eli Lilly and in a research note on Monday, July 17th. Berenberg Bank reaffirmed a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a research note on Thursday, July 27th. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a research note on Tuesday, July 4th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and an average price target of $87.97.

In other Eli Lilly and news, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the transaction, the insider now directly owns 14,041 shares in the company, valued at approximately $1,134,231.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the firm’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. Insiders have sold a total of 849,733 shares of company stock worth $70,436,087 over the last 90 days. 0.20% of the stock is currently owned by company insiders.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.